Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1652 1653 1656 1683 1759 1799
This examiner grants 73% of resolved cases
Suzanne Marie Noakes works in Tech Center 1700 and Art Unit 1652. The profile shows a high volume of 1075 resolved cases and an allowance rate of 73.3%. This 73.3% rate provides a clear baseline for the probability of reaching a patent grant. The median days to allowance is 946, which indicates a relatively efficient prosecution process. With 1075 resolved cases, the statistical confidence in these metrics is very high.
The interview lift is 18.2%, showing that interviews are an effective way to improve the 73.3% baseline allowance rate. Practitioners should consider an interview to resolve issues and potentially maintain the 946-day timeline. The 18.2% lift indicates that verbal advocacy is a productive tactic for this examiner. Applicants can expect a clear path to grant based on the 946 median days to allowance. This analysis of Art Unit 1652 is based on the 1075 resolved cases available.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18743008 | ACTIVATABLE NANOREPORTERS FOR REAL-TIME TRACKING OF MACROPHAGE PHENOTYPIC STATES ASSOCIATED WITH DISEASE PROGRESSION | Non-Final OA | University of Massachusetts |
| 18458443 | PLANT GROWTH PROMOTER PRODUCTION METHOD, PLANT GROWTH PROMOTER, AND PLANT GROWTH PROMOTING METHOD | Non-Final OA | Panasonic Intellectual Property Management Co., Ltd. |
| 18309003 | RECOMBINANT PROTEINS FOR QUANTIFICATION OF PROTEIN LEVELS | Non-Final OA | Genentech, Inc. |
| 18691748 | MODIFIED PROTEIN DISULFIDE ISOMERASE AND USES THEREOF | Final Rejection | The University of North Carolina at Chapel Hill |
| 18764634 | RNA-Guided Targeting of Genetic and Epigenomic Regulatory Proteins to Specific Genomic Loci | Final Rejection | The General Hospital Corporation |
| 18261264 | SUPRAMOLECULAR ASSEMBLIES, COMPOSITIONS AND METHODS FOR PRODUCING AND USING THE SAME | Non-Final OA | PURDUE RESEARCH FOUNDATION |
| 18838044 | PROCESS FOR WHOLE-CELL BIOSYNTHESIS OF STYRENE | Non-Final OA | SHELL USA, INC. |
| 19103587 | EXPRESSION SYSTEMS FOR PHOSPHATASES | Non-Final OA | INTERNATIONAL N&H DENMARK APS |
| 18855856 | NOVEL LIPASE | Non-Final OA | KAO CORPORATION |
| 18262051 | LIPASE WITH LOW MALODOR GENERATION | Non-Final OA | Novozymes A/S |
| 17923489 | MEDICAL CLEANING COMPOSITION, USE AND METHOD OF CLEANING | Non-Final OA | Novozymes A/S |
| 18473622 | Methods Of Treating Fabry Disease In Patients Having A Mutation In The GLA Gene | Non-Final OA | Amicus Therapeutics, Inc. |
| 17919710 | REGULATORY NUCLEIC ACID SEQUENCES | Final Rejection | ASKLEPIOS BIOPHARMACEUTICAL, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy